1. Evaluation of 5 Commercially Available Zika Virus Immunoassays
- Author
-
Kimberly Holloway, Kai Makowski, Joanne Hiebert, Sharla Beddome, Michael A. Drebot, Rhonda Mogk, Nicole Barairo, Emelissa J Mendoza, Alyssia Robinson, David Safronetz, Charlene Ranadheera, Angela Sloan, Leanne Scharikow, Elizabeth Giles, Kristina Dimitrova, Derek R. Stein, and Maya Traykova-Andonova
- Subjects
0301 basic medicine ,Microbiology (medical) ,Canada ,IgM ,Epidemiology ,Expedited ,IgM-capture ELISA ,vector-borne infections ,030231 tropical medicine ,030106 microbiology ,Mac elisa ,lcsh:Medicine ,specificity ,Enzyme-Linked Immunosorbent Assay ,Antibodies, Viral ,Sensitivity and Specificity ,Neutralization ,lcsh:Infectious and parasitic diseases ,Zika virus ,Serology ,03 medical and health sciences ,0302 clinical medicine ,Neutralization Tests ,Humans ,Medicine ,lcsh:RC109-216 ,viruses ,Immunoassay ,evaluation ,biology ,Zika Virus Infection ,business.industry ,lcsh:R ,Dispatch ,sensitivity ,biology.organism_classification ,Virology ,zoonoses ,immunoassays ,Infectious Diseases ,Immunoglobulin M ,Immunoglobulin G ,Immunology ,Evaluation of 5 Commercially Available Zika Virus Immunoassays ,ELISA ,MAC-ELISA ,business - Abstract
Because of the global spread of Zika virus, accurate and high-throughput diagnostic immunoassays are needed. We compared the sensitivity and specificity of 5 commercially available Zika virus serologic assays to the recommended protocol of Zika virus IgM-capture ELISA and plaque-reduction neutralization tests. Most commercial immunoassays showed low sensitivity, which can be increased.
- Published
- 2017